The Work Environment and Healthcare Provider Recommendation of the HPV Vaccine

Rula Btoush, PhD, RN Associate Professor




Disclosures

Disclosures	
Author:	Rula Btoush
Employer:	Rutgers University
Sponsor:	Rutgers Cancer Institute of New Jersey (RCINJ)
Commercial Support:	None
Conflict of Interest:	None

Background - HPV Vaccination

- The CDC recommends routine use of HPV vaccine for females and males beginning at age 11 years
- The President's Cancer Panel's (PCP) report on accelerating HPV vaccine uptake:
 - First goal: reduce missed clinical opportunities to recommend and administer HPV vaccine
- Healthy People 2020:
 - 80% HPV vaccine uptake among female adolescents
- Nationally, HPV vaccine initiation is 66% among adolescents 13-17 years old (2017 NIS-Teen survey)



Note: Rates are based on data from the New Jersey Immunization Information System (NJIIS)

Background - Role of HCPs

- The importance of healthcare providers' (HCPs) recommendation in the HPV vaccine decision—making process
- Yet, HCPs are not discussing the HPV vaccine with parents
- Studies are still lacking in understanding factors that influence HCP's recommendation, particularly in samples that represent HCP specialties and professions

Study Purpose and Questions


- The purpose of this study was to examine HCP recommendation of the HPV vaccine and their knowledge, beliefs, perceived barriers, and cues to action for recommending the HPV vaccine.
- Research questions:
 - What are the HCP's knowledge and beliefs about the HPV vaccine?
 - 2. What are the <u>most common perceived barriers</u> for HCP's HPV vaccine recommendation?
 - 3. Which <u>combination of predictors</u> are associated with HCP recommendation for HPV vaccination?

Methods


- Online survey of 389 HCPs in New Jersey
- Survey questions on:
 - HCP recommendation of the HPV vaccine
 - Knowledge and beliefs about the vaccine
 - Barriers (parent-related and system-related barriers)
 - Cues to action (facilitators) for recommending the HPV vaccine
- Email announcements via VFC program, NJAAP, APN-NJ, and other collaborators and through word of mouth

Survey Participants (N=389)


Gender	Male Female	28% 72%
Specialty	Pediatrics Women's Health or OB/GYN Family Medicine/Health	62% 18% 20%
Healthcare Profession	Physician Nurse Practitioner	75% 25%
Practice Type	Private Practice Public Clinic FQHC Other	58% 16% 13% 13%




HCP's Knowledge about the HPV Vaccine




HCP's Beliefs about the HPV Vaccine




<u>Parent-Related Barriers</u> for HCP's Recommendation of the HPV Vaccine




<u>System-Related Barriers</u> for HCP's Recommendation of the HPV Vaccine



Cues to Action (facilitators) for HCP's Recommendation of the HPV Vaccine



Cues to Action (facilitators) for HCP's Recommendation of the HPV Vaccine



Logistic regression analysis of HCP's recommendation of HPV vaccination

Predictors - Patient Characteristics (N=351)	OR	95% CI
% of male patients in your practice	.989	.974 - 1.005
% HPV-vaccine eligible patients	1.009	1.001 - 1.017
% of younger adolescents (11-13 years old)	1.015	1.001 - 1.029
% of Black patients	1.022	1.003 - 1.041
% of Hispanic patients	1.032	1.014 - 1.050
% of patient with private insurance	1.034	1.019 - 1.050
% of VFC recipients	1.017	1.004 - 1.030
Constant	.034	
Omnibus Tests of Model Coefficients: X ² (P)	56.666 (<0.001)	
Model Summary: -2 Log likelihood; Nagelkerke R ²	362.795; <mark>21.4%</mark>	
Predictors – HCP's Characteristics (N=383)	OR	95% CI
Specialty (pediatric vs. non-pediatric)	2.484	1.450 - 4.255
Knowledge	9.210	3.452 - 24.574
Perceived effectiveness	1.435	.889 - 2.316
Perceived concerns	.483	.294793
Perceived barriers - communicating with parents	.959	.321 - 2.863
Perceived barriers - system-related	.524	.237 - 1.157
Cues to action	1.686	.907 - 3.134
Constant	.001	
Omnibus Tests of Model Coefficients: X ² (P)	120.722 (<0.001)	
Model Summary: - 2 Log likelihood; Nagelkerke R ²	345.665; <mark>38.4%</mark>	

Logistic regression analysis of predictors for HCP's recommendation of HPV vaccination, using backward stepwise Wald method (N=345)

Surviving Predictors:	OR	95% CI
% of Black patients	1.030	1.009 - 1.052
% of Hispanic patients	1.043	1.022 - 1.065
% of patient with private insurance	1.019	1.006 - 1.032
HCP's specialty (pediatric vs. non-pediatric)	2.656	1.460 - 4.831
HCP's knowledge	10.390	3.314 - 32.576
HCP's perceived concerns	.397	.236669
HCP's perceived system-related barriers	.415	.174988
HCP's cues to action	2.128	1.089 - 4.158
Constant	.000	
Omnibus Tests of Model Coefficients: X ² (P)	124.	197 (<0.001)
Model Summary: -2 Log likelihood; Nagelkerke R ²	289.392; <mark>43.3%</mark>	

Factors that Influence HCP's Recommendation of the HPV Vaccine

- Higher rates HCPs recommending HPV vaccination among/with:
 - Pediatric vs. non-pediatric providers
 - Higher levels of knowledge
 - Lower levels concerns about the HPV vaccine
 - Lower levels of system-related barriers
 - Higher levels of cues to action (facilitators)

Implications

- HCP interventions on HPV vaccination have the potential for long-term reductions in HPV-related cancers
- The need for integrated, comprehensive communication strategies for HCPs and for improving the work environment to optimize patient outcomes related to HPV vaccination
- The study findings inform the development of interventions and strategies to establish healthy working practices and environments in order to reach *Healthy People 2020's* objective of 80% coverage for HPV vaccination among adolescents

For more information, contact Rula Btoush, PhD, RN at 973-353-5650 or

Rula.Btoush@Rutgers.edu

Acknowledgement of Collaborators:

- Diane Brown, PhD; Rutgers School of Public Health
- Dennis Carmody, PhD; Rutgers School of Nursing
- Shawna Hudson, PhD; Robert Wood Johnson Medical School (RWJMS)
- Lindsey Toller, MPH; Rutgers School of Public Health
- Jennifer Tsui, PhD, Rutgers Cancer Institute of New Jersey (RCINJ)
- Michael Weinstein, NJ Chapter American Academy of Pediatrics (AAP)
- NJDOH Vaccine Preventable Diseases (VPD) Program and the Vaccines For Children (VFC) Program